CRISPR and Gene Editing: A Game-Changer in Drug Development

Curr Pharm Des. 2024 Apr 4. doi: 10.2174/0113816128298080240328053845. Online ahead of print.ABSTRACTCRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. However, alongside its promise, ethical considerations loom large, particularly regarding germline editing and equitable access to treatments. The commercialization of CRISPR poses further challenges, raising questions about affordability and healthcare equity. Collaboration among scientists, policymakers, and the public is emphasized to navigate the ethical and societal implications of CRISPR responsibly. As the field advances, it is essential to ensure that the benefits of CRISPR are realized while addressing potential risks and maintaining a commitment to the well-being of future generations.PMID:38584552 | DOI:10.2174/0113816128298080240328053845
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Source Type: research